Pheochromocytomas Approved for Marketing Phase Trials for Iobenguane (DB06704)

Also known as: Pheochromocytoma / Chromaffin cell neoplasm (morphologic abnormality) / Phaeochromocytoma / Pheochromocytoma (morphologic abnormality) / Phaeochromocytoma [Ambiguous]

IndicationStatusPhase
DBCOND0071316 (Pheochromocytomas)Approved for MarketingNot Available
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01377532Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma
NCT02961491Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma